anti-.... cholenergics, n/v,Oxytocin, octreotide Flashcards
MOA for Anticholinergics
Aromatic esters that competitively inhibit the effects of ACh at the muscarinic receptors thereby decreasing PNS activity (prevent c AMP and cGMP effects); used for symptomatic brady, anti-sialagogue, Gi spasms and decreases GI secretions, bronchodilation, pea, systole, promotes AW relaxation by inhibing the M2 and M3 causing bronchial SM relaxation and increase HR by blocking the ACh effects at SA node; use with NMB reversal agent
Atropine PK
40%PB to alpha-1-glycoprotein, Vd=1.6L/KG, onset 1 min, peak 1-2min, Do a 30-60min, e1/2 2 hours, hydrolyzed in the liver to tropine and tropic acid and excreted 18% unchanged in the urine
Atropine Se
sedation bc crosses bbb, increases HR, CO, IOP, arrhythmias, blurry vision, decrease secretions and GI motility, bronchodilation
Atropine class
tertiary amine anticholinergic
Atropine CI
glaucoma, patients that tachycardia would be harmful- such as-CAD, hyperpyrexia pts, mobitz type 2
avoid other sympathomimetics
Atropine Dose
0.01mg/kg for reversal; 0.4-0.6 preop antisialagogue, 0.4-1mg for bradycardia; 1mg q3-5min for systole/PEA
Glycopyrrolate class
synthetic quaternary ammonium anticholinergic
Glycopyrrolate Pk
onset 2-3 min, peak 3-5min, DOA 2-4 hours, e1/2 1hour, liver metabolism and 85% excreted unchanged in the urine, poorly lipid soluble
Glycopyrrolate SE
increase HR, CO, IOP, arrhythmias, H/A, blurry vision, decrease secretions and go motility, bronchodilation, MH, decreases sweating, anaphylactic reaction
Glycopyrrolate CI
MH, neonates, CAD, HTN, CHF, glaucoma, hyperpyrexia pts
Glycopyrrolate dose
reversal 0.01-0.02mg/kg IV
anti-sialagogue and bradycardia 0.1-0.2mg
Scopolamine- class
tertiary amine anticholinergic
used for motion sickness, PONV, sedation, bronchodilation; biliary and ureteral SM relaxation, NOT USED FOR REVERSAL NMB
Scopolamine Pk
lipid soluble, onset 10 min, DOA 2 hours, e1/2 4 hours, may last 3-7 days, metabolized by the liver with <1% excreted unchanged in the urine
Scopolamine SE
increase HR, CO, IOP, OH. sedation, arrhythmias, blurry vision. decreases secretions and GI motility
Scopolamine CI
glaucoma liver disease, GI/GU obstruction
Scopolamine dose
0.3-0.6mg IV q4-6 hours
Metoproclamide/reglan
antiemetic, dopamine receptor antagonist and serotonin receptor agonist
Metoproclamide/reglan MOA
blocks the DA2 receptors in the chemo receptor trigger zone of the medullar preventing N/V; also a pro kinetic increasing gastric motility via serotonin increasing peristalsis and increases ACh at the muscarinic receptors post synaptically
Metoproclamide/reglan PK
onset 1-3 min, DOA 1-2 HR, e1/2 2-4hours, metabolized in the liver and 40% excreted unchanged in the urine
Metoproclamide/reglan SE
increase gastric motility, LES tone, decrease N/V, extrapyramidal SE, abd cramping, sedation, prolactin secretion, dry mouth, good for RSI
Metoproclamide/reglan CI
Parkinsons, bowel obstruction, GI hemorrhage, sz, arrhythmias esp if administered with zofran, no phenothiazides
Increased sedative effects of Cns depressants
Metoproclamide/reglan dose
10-20mg iv over 3-5min 15 min before induction
10mg preinduction pt with gastroparesis
0.15/kg mom ponv and kid
Ondansetron/Zofran class
antiemetic, serotonin antagonist
Ondansetron/Zofran MOA
blocks the serotonin receptors peripherally and in the CRTz- coupled to fast sodium channels and k channels
Ondansetron/Zofran PK
onset 30min, DOA 4-8hours, e1/2 3-4 hours, metabolized in the liver with renal excretion 5% unchanged
Ondansetron/Zofran SE
HA with rapid administration, sedation, arrhythmias, constipation, diarrhea, fatigue
Ondansetron/Zofran CI
hypersensitivity, liver disease, SSRIs, MAOis
Ondansetron/Zofran dose
4-8mg IV over 2-5min
Promethazine/Phenergan class
antiemetic, H1 and Dopamine 2 antagonist.
Promethazine/Phenergan MOA
blocks DA receptors and antagonizes H1 @ receptor. response decreases histamine mediated release in respiratory tract, GI and blood vessels
Promethazine/Phenergan Pk
93%PB, onset 3-5min, DOA 2-4 hours, e1/2 9-16hours, metabolized in the liver by CYP450 and excreted in the urine
Promethazine/Phenergan SE
extrapyramidal effects, anticholinergic effects, sedation, arrhythmias, neuroleptic malignant syndrome
Promethazine/Phenergan CI
hypersensitivity, parkinson’s on levodopa, rena/hepatic/pulmonary diseases, peds <2yrs
Promethazine/Phenergan dose
6.25-25mg IB
Omeprazole/Prilosec class
Antiemetic/ PPI
Omeprazole/Prilosec MOA
prodrug that irreversibly inhibits H=/K= ATPase proton pump in the parietal cells decreasing gastric secretion
Omeprazole/Prilosec PK
95% PB, onset 1hr, DOA 72 hr, metabolized in the liver by CYP 2C19 to inactive metabolites
Omeprazole/Prilosec SE
HA, confusion, agitation, dizziness, N/V/D, abd pain
Omeprazole/Prilosec CI
hyprsensitivity, prolongs metabolism of diazepam, warfarin, dilantin
Omeprazole/Prilosec dose
40mg IV
Octreotide class
somatostatin analog
Octreotide MOA
binds to somatostatin receptor on carcinoid tumors to decrease the amount of serotonin released from tumors and decrease vasoactive amides; inhibits the production and release of GH, glucagon and insulin
Octreotide pk
65% PB, onset rapid, peak 2 hours; E1/2 2 hours; liver metabolism and excreted 32% unchanged in the urine
Octreotide SE
decrease glucose tolerance, hyperglycemia, N/V/C, decreases GI motility, gallstones, bradycardia, AV block
Octreotide CI
hypersensitivity, decreases effects of codeine and cyclosporine
Octreotide dose
50-100mcg/hr; 25-200mcg prn; 25-50mcg/hr for varices
Oxytocin class
endogenous posterior pituitary hormone
Oxytocin MOA
binds to oxytocin receptors on the uterus= SM contraction; used to induce or augment labor and contract the uterus post delivery and decrease chance of hemorrhage
Oxytocin PK
onset 1 min, DOA 1hour, E1/2 3-5min; metabolized by the liver and kidney; broken down by plasma oxytocinase and metabolism in mammary gland
Oxytocin SE
mom- anaphylaxis, N/V, PP hemorrhage, uterine rupture, arrhythmias and PVCs; baby- bradycardia, problematic fetal positioning, fetal distress
Oxytocin CI
fetal distress, hypertonic contractions, hypersensitivity
Oxytocin dose
10-40 units in 1L at 0.5-2mU/min ( increase gtt q15 min by 0.5-2mU/min until contractions are 2-3 min apart)